Immunetrics’ disease models span across acute inflammation, chronic, autoimmune conditions, and immuno-oncology.
These models can be customized to meet specific needs and are constantly evolving to support new research outcomes.
Disease Models |
Key Outputs |
Supported Therapeutics |
Rheumatoid Arthritis
|
Swollen/tender joint counts (SJC/TJC) ACR20/50/70/90 DAS28(3)-CRP/ESR Low disease activity Remission Serum cytokines and biomarkers Serum cell counts |
MTX 5-ASA Corticosteroids JAK inhibitors Anti-TNFs Anti-IL6s Anti-IL17s Anti-T and B cell therapies Anti-Survival therapies Anti-Migration therapies |
Psoriatic Arthritis / Psoriasis |
Swollen/tender joint counts ACR20/50/70 DAS28(3)-CRP/ESR PASI 50/75/90/100 Serum cytokines and biomarkers Serum cell counts |
MTX 5-ASA Corticosteroids JAK inhibitors Anti-TNFs Anti-IL6s Anti-IL17s Anti-IL12/23 Anti-T and B cell therapies Anti-Survival therapies Anti-Migration therapies |
Ulcerative Colitis |
Mayo score Response/Remission Mucosal healing Serum cytokines and biomarkers |
MTX 5-ASA Corticosteroids Anti-TNFs JAK inhibitors S1P receptor antagonist |
Acute Myeloid Leukemia (AML) |
Best Overall Response (BOR) based on bone marrow and blood blast counts:
Response vs Non-response Minimal Residual Disease (MRD = < 0.1% Blasts) Death Duration of Response (DoR) Relapse Disease-specific Biomarkers:
|
Hypomethylating Agents (i.e. azacytidine) Chemotherapies (cytarabine) BCL-2 inhibitor (venetoclax) Monoclonal antibodies (e.g. anti-CD47) |
Multiple Myeloma (MM) |
Best Overall Response (BOR) based on M-protein changes:
Overall Response Rate (ORR) Time To Response (TTR) Duration of Response (DoR) Disease-specific Biomarkers:
|
Immunomodulatory Drugs (IMiDs) Antibody-Drug Conjugates (ADCs) Immune Cell Engagers (NK and T cell Engagers) Monoclonal Antibodies (e.g. Daratumumab) Chimeric Antigen Receptor T cell Therapies (CAR T therapies) Steroids (i.e. Dexamethasone) |
Melanoma* |
Tumor Size Best Overall Response (BOR) |
Client Proprietary |
Non-small cell lung cancer (NSCLC)* |
Percent change in Tumor Diameter Best Overall Response (BOR) Progressive Disease (PD) Stable Disease (SD) Responders (RR) |
Monoclonal Antibodies
Chemotherapies
|
Diffuse large B cell lymphoma (DLBCL)* |
Complete Responder (CR) Partial Responder (PR) Tumor Cell Number |
Chimeric Antigen Receptor T cell Therapies (CAR T therapies)
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) Immunomodulatory Drugs (IMiDs)
|
Sepsis Multi-Organ Dysfunction
|
Mean arterial pressure (MAP) Central venous pressure (CVP) Blood oxygen saturation (O2sat) Breathing frequency Tidal volume Blood gases (PaO2, PaCO2) Creatinine Urinary output (UOP) Coagulation proteins |
Fluid therapy Vasopressors Ventilators Diuretics Dialysis Antibiotics |
Trauma |
Cytokines Immune cells Coagulation proteins Blood loss Mean arterial pressure (MAP) Blood oxygen saturation (O2sat) |
Fluid therapies Blood products Ventilators |
* Indicates models developed internally OR for a specific purpose. These models are currently limited in functionality compared to our platform models.